Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma

Seminars in Nuclear Medicine

Volumn 41, Issue 2, 2011, Pages 139-148

  Biermann, Kim ^a   Biersack, Hans Jürgen ^a   Sabet, Amir ^a   Janzen, Viktor ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NAL3 OCTREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE; ALPHA INTERFERON; AXITINIB; CELECOXIB; CISPLATIN; DOXORUBICIN; GEFITINIB; LENALIDOMIDE; MOTESANIB; OCTREOTIDE; PAZOPANIB; RADIOACTIVE IODINE; RETINOIC ACID; ROSIGLITAZONE; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANXIETY; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; GASTROINTESTINAL DISEASE; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; METASTASIS; MOUTH DISEASE; MOUTH SORE; MUSCULOSKELETAL PAIN; NAUSEA; PROGNOSIS; PRURITUS; QUALITY OF LIFE; SIDE EFFECT; STOMATITIS; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 79251524248     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2010.10.005     Document Type: Review

References (95)

1. C. Durante, N. Haddy, and E. Baudin Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J Clin Endocrinol Metab 91 2006 2892 2899
2. C. Cappelli, I. Pirola, and M. Braga Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution Ann Ital Chir 77 2006 107 113
3. F. Raue German medullary thyroid carcinoma/multiple endocrine neoplasia registry German MTC/MEN Study Group: Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2 Langenbecks Arch Surg 383 1998 334 336
4. T. Grning, C. Tiepolt, and K. Zphel Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? Eur J Endocrinol 148 2003 395 402
5. F. Grnwald, C. Menzel, and H. Bender Redifferentiation therapy-induced radioiodine uptake in thyroid cancer J Nucl Med 39 1998 1903 1906
6. C.A. Fernndez, M. Puig-Domingo, and F. Lomea Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake J Endocrinol Invest 32 2009 228 233
7. W.G. Kim, E.Y. Kim, and T.Y. Kim Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer Endocr J 56 2009 105 112
8. D. Simon, C. Krber, and M. Krausch Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study Eur J Nucl Med Mol Imaging 29 2002 775 782
9. D. Simon, J. Koehrle, and C. Reiners Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma World J Surg 22 1998 569 574
10. S.I. Sherman Targeted therapy of thyroid cancer Biochem Pharmacol 80 2010 592 601
11. K. Shimaoka, D.A. Schoenfeld, and W.D. DeWys A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer 56 1985 2155 2160
12. J.H. Kim, and R.D. Leeper Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy Cancer 60 1987 2372 2375
13. J.A. Gottlieb, and B. Drewinko Review of the current clinical status of platinum coordination complexes in cancer chemotherapy Cancer Chemother Rep 59 1975 621 628
14. A. Argiris, S.S. Agarwala, and M.V. Karamouzis A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer Invest New Drugs 26 2008 183 188
15. J.A. Fagin, and N. Mitsiades Molecular pathology of thyroid cancer: diagnostic and clinical implications Best Pract Res Clin Endocrinol Metab 22 2008 955 969
16. M. Schlumberger, F. Carlomagno, and E. Baudin New therapeutic approaches to treat medullary thyroid carcinoma Nat Clin Pract Endocrinol Metab 4 2008 22 32
17. C. Lanzi, G. Cassinelli, and V. Nicolini Targeting RET for thyroid cancer therapy Biochem Pharmacol 77 2009 297 309
18. S.L. Sugg, S. Ezzat, and I.B. Rosen Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia J Clin Endocrinol Metab 83 1998 4116 4122
19. M.N. Nikiforova, E.T. Kimura, and M. Gandhi BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas J Clin Endocrinol Metab 88 2003 5399 5404
20. J.A. Knauf, and J.A. Fagin Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets Curr Opin Cell Biol 21 2009 296 303
21. S.M. Coelho, D.P. de Carvalho, and M. Vaisman New perspectives on the treatment of differentiated thyroid cancer Arq Bras Endocrinol Metab 51 2007 612 624
22. E.Y. Soh, Q.Y. Duh, and S.A. Sobhi Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid J Clin Endocrinol Metab 82 1997 3741 3747
23. B. Saller, G. Stapfer, and B. Bein Increased binding capacity of receptors for the epidermal growth factor in benign thyroid nodules and thyroid malignancies Clin Invest 71 1993 898 902
24. K.T. Chen, J.D. Lin, and M.J. Liou An aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell lines Cancer Lett 231 2006 192 205
25. R.T. Kloos, M.D. Ringel, and M.V. Knopp Phase II trial of sorafenib in metastatic thyroid cancer Clin Oncol 27 2009 1675 1684
26. V. Gupta-Abramson, A.B. Troxel, and A. Nellore Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 26 2008 4714 4719
27. H. Hoftijzer, K.A. Heemstra, and H. Morreau Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma Eur J Endocrinol 161 2009 923 931
28. S.G. Waguespack, S.I. Sherman, and M.D. Williams The successful use of sorafenib to treat pediatric papillary thyroid carcinoma Thyroidology 19 2009 407 412
29. M.E. Cabanillas, S.G. Waguespack, and Y. Bronstein Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience J Clin Endocrinol Metab 95 2010 2588 2595
30. Cohen EE, Needles BM, Cullen KJ,, et al. Phase 2 study of sunitinib in refractory thyroid cancer, in Proceedings of the From The ASCO Annual Meeting; Chicago, IL, 2008
31. Ravaud A, de la Fouchardire C, Courbon F,, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial, in Proceedings of the From The ASCO Annual Meeting; Chicago, IL, 2008
32. L.L. Carr, D. Mankoff, and B.H. Goulart Phase II study of sunitinib in FDG-PET positive, differentiated thyroid cancer and metastatic medullary carcinoma of thyroid with functional imaging correlation Clin Cancer Res 16 2010 5260 5268
33. Rosen LS, Kurzrock R, Mulay M,, et al. Safety, Pharmacokinetics, and Efficacy of AMG 706: An Oral Multikinase Inhibitor, in Patients with Advanced Solid Tumors, in Proceedings from the Asco Annual Meeting; Chicago, IL, 2007
34. S.I. Sherman, L.J. Wirth, and J.P. Droz Motesanib diphosphate in progressive differentiated thyroid cancer N Engl J Med 359 2008 31 42
35. E.E. Cohen, L.S. Rosen, and E.E. Vokes Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 2008 4708 4713
36. K.C. Bible, V.J. Suman, and J.R. Molina Efficacy of pazopanib in progressive, radioiodine refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study Lancet Oncol 11 2010 962 972
37. Pennell NA, Daniels GH, Haddad RI,, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Proceedings of the From The ASCO Annual Meeting; Chicago, IL, 2007
38. K.B. Ain, C. Lee, and K.D. Williams Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas Thyroidology 17 2007 663 670
39. Ain KB, Lee C, Holbrook KM,, et al. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results, in Proceedings of the From The ASCO Annual Meeting; Chicago, IL, 2008
40. R. Lapalombella, L. Andritsos, and Q. Liu Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway Blood 115 2010 2619 2629
41. Piekarz R, Luchenko V, Draper D,, et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers, in Proceedings of the From The ASCO Annual Meeting; Chicago, IL, 2008
42. Sherman EJ, Fury MG, Tuttle RM,, et al. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma, in Proceedings of the From The ASCO Annual Meeting; Orlando, 2009
43. J.A. Woyach, R.T. Kloos, and M.D. Ringel Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma J Clin Endocrinol Metab 94 2009 164 170
44. W.K. Kelly, O.A. O'Connor, and L.M. Krug Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 2005 3923 3931
45. F. Braiteh, A.O. Soriano, and G. Garcia-Manero Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers Clin Cancer Res 14 2008 6296 6301
46. E. Mrozek, R.T. Kloos, and M.D. Ringel Phase II study of celecoxib in metastatic differentiated thyroid carcinoma J Clin Endocrinol Metab 91 2006 2201 2204
47. M.B. Casey, S. Zhang, and L. Jin Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions Endocr Pathol 15 2004 107 116
48. M.C. Specht, O.N. Tucker, and M. Hocever Cyclooxygenase-2 expression in thyroid nodules J Clin Endocrinol Metab 87 2008 358 363
49. A.J. Cornetta, J.P. Russell, and M. Cunnane Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis Laryngoscope 112 2002 238 242
50. E. Seregni, C. Vellani, and R. Castellani Redifferentiating agents in non-radioiodine avid cancer Q J Nucl Med Mol Imaging 53 2009 513 519
51. J. Kurebayashi, K. Tanaka, and T. Otsuki All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1 J Clin Endocrinol Metab 85 2000 2889 2896
52. H. Jeong, Y.R. Kim, and K.N. Kim Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line Nucl Med Biol 33 2006 875 882
53. D. Handkiewicz-Junak, J. Roskosz, and K. Hasse-Lazar 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study Thyroid Res 2 2009 8
54. E. Frhlich, F. Machicao, and R. Wahl Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture [Erratum in: Endocr Relat Cancer 12:681, 2005] Endocr Relat Cancer 12 2005 291 303
55. M.L. Martelli, R. Iuliano, and I. Le Pera Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth J Clin Endocrinol Metab 87 2002 4728 4735
56. E. Kebebew, S. Lindsay, and O.H. Clark Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer Thyroidology 19 2009 953 956
57. A. Hofmann, P. John, and M.P. Schaffarich Statins as a new therapeutic approach in dedifferentiated thyroid cancer? A Case report World J Nucl Med 4 Suppl 1 2005 [Abstract 004-AUS]
58. P.T. Postema, W.W. De Herder, and J.C. Reubi Somatostatin receptor scintigraphy in non-medullary thyroid cancer Digestion 57 1996 36 37
59. L.M. Haslinghuis, E.P. Krenning, and W.W. De Herder Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer J Endocrinol Invest 24 2001 415 422
60. J.A. Christian, G.J. Cook, and C. Harmer Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid Br J Cancer 89 2003 258 261
61. M.P. Stokkel, H.I. Reigman, and R.B. Verkooijen Indium-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131 J Cancer Res Clin Oncol 129 2003 287 294
62. M. Middendorp, I. Selkinski, and C. Happel Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data Q J Nucl Med Mol Imaging 54 2010 76 83
63. R. Valkema, M. De Jong, and W.H. Bakker Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience Semin Nucl Med 32 2002 110 122
64. L.B. Anthony, E.A. Woltering, and G.D. Espenan Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies Semin Nucl Med 32 2002 123 132
65. G. Paganelli, L. Bodei, and D. Handkiewicz Junak 90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies Biopolymers 66 2002 393 398
66. R. Valkema, S. Pauwels, and L.K. Kvols Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors Semin Nucl Med 36 2006 147 156
67. D.J. Kwekkeboom, W.W. de Herder, and B.L. Kam Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2008 2124 2130
68. C. Waldherr, M. Pless, and H.R. Maecke The clinical value of [90Y-DOTA]-D-Phe1Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study Ann Oncol 12 2001 941 945
69. D.J. Kwekkeboom, B.L. Kam, and M. van Essen Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors Endocr Relat Cancer 17 2010 R53 R73
70. J.J. Teunissen, D.J. Kwekkeboom, and P.P. Kooij Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma J Nucl Med 46 2005 107S 114S
71. R. Grges, G. Kahaly, and J. Mller-Brand Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer Thyroidology 11 2001 647 659
72. C. Waldherr, T. Schumacher, and M. Pless Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using Nucl Med Commun 22 2001 673 678
73. I. Virgolini, K. Britton, and J. Buscombe In- and Y-DOTA-lanreotide: results and implications of the Mauritius trial Semin Nucl Med 32 2002 148 155
74. M. Chinol, L. Bodei, and M. Cremonesi Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group Semin Nucl Med 32 2002 141 147
75. M. Gabriel, F. Froehlich, and C. Decristoforo 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative 131I whole-body scans Eur J Nucl Med Mol Imaging 31 2004 330 341
76. M.P. Stokkel, R.B. Verkooijen, and H. Bouwsma Six-month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine nonresponsive thyroid cancer: a pilot study Nucl Med Commun 25 2004 683 690
77. J.C. Reubi, B. Waser, and J.C. Schaer Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur J Nucl Med 28 2001 836 846
78. K.B. Ain, K.D. Taylor, and S. Tofiq Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines J Clin Endocrinol Metab 82 1997 1857 1862
79. J.C. Reubi, J.C. Schar, and B. Waser Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 2000 273 282
80. S. Roman, R. Lin, and J.A. Sosa Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases Cancer 107 2006 2134 2142
81. F.W. Hanna, J.E. Ardill, and C.F. Johnston Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid J Endocrinol 152 1997 275 281
82. D. Freeman, and S. Lindsay Medullary carcinoma of the thyroid gland Arch Pathol 80 1965 575 582
83. G. Vitale, M. Caraglia, and A. Ciccarelli Current approaches and perspectives in the therapy of medullary thyroid carcinoma Cancer 91 2001 1797 1808
84. S. Leboulleux, E. Baudin, and J.P. Travagli Medullary thyroid carcinoma Clin Endocrinol (Oxf) 61 2004 299 310
85. J.F. Chatal, L. Campion, and F. Kraeber-Bodr Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group J Clin Oncol 24 2006 1705 1711
86. V. Rufini, M. Salvatori, and M.C. Garganese Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma Rays 25 2000 273 282
87. J.L. Baulieu, D. Guilloteau, and M.J. deLisle Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer A French cooperative study Cancer 60 1987 2189 2194
88. C.A. Hoefnagel, C.C. Delprat, and R.A. Valds Olmos Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma J Nucl Biol Med 35 1991 334 336
89. K. Zaplatnikov, C. Menzel, and N. Dbert Case report: drug interference with MIBG uptake in a patient with metastatic paraganglioma Br J Radiol 77 2004 525 527
90. F. Grnwald, and S. Ezziddin 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors Semin Nucl Med 40 2010 153 163
91. Z. Gao, H.J. Biersack, and S. Ezziddin The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy J Cancer Res Clin Oncol 130 2004 649 656
92. V. Rufini, P. Castaldi, and G. Treglia Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma Biomed Pharmacother 62 2008 139 146
93. M.R. Castellani, A. Alessi, and G. Savelli The role of radionuclide therapy in medullary thyroid cancer Tumori 89 2003 560 562
94. C.A. Hoefnagel MIBG and radiolabeled octreotide in neuroendocrine tumors Q J Nucl Med 39 1995 137 139
95. M.R. Castellani, E. Seregni, and M. Maccauro MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging 52 2008 430 440